"Raloxifene Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.
Descriptor ID |
D020849
|
MeSH Number(s) |
D02.455.426.559.389.150.700.900.775
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Raloxifene Hydrochloride".
Below are MeSH descriptors whose meaning is more specific than "Raloxifene Hydrochloride".
This graph shows the total number of publications written about "Raloxifene Hydrochloride" by people in this website by year, and whether "Raloxifene Hydrochloride" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 0 | 1 | 1 |
2000 | 1 | 0 | 1 |
2005 | 1 | 0 | 1 |
2013 | 1 | 0 | 1 |
2014 | 1 | 0 | 1 |
2016 | 0 | 1 | 1 |
2017 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Raloxifene Hydrochloride" by people in Profiles.
-
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017 08; 69(8):1521-1537.
-
Layered double hydroxides as effective carrier for anticancer drugs and tailoring of release rate through interlayer anions. J Control Release. 2016 Feb 28; 224:186-198.
-
Raloxifene and antiestrogenic gonadorelin inhibits intestinal tumorigenesis by modulating immune cells and decreasing stem-like cells. Cancer Prev Res (Phila). 2014 Mar; 7(3):300-9.
-
Chemopreventive efficacy of raloxifene, bexarotene, and their combination on the progression of chemically induced colon adenomas to adenocarcinomas in rats. Cancer Prev Res (Phila). 2013 Dec; 6(12):1251-61.
-
The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation. J Immunol. 2005 Aug 15; 175(4):2666-75.
-
The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2000 Jan; 85(1):214-8.
-
Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998 May 13; 279(18):1445-51.